| Ytd | 123.23% | |
| 1y | 45.38% |
| Open | 27.60 | Prev Close | 27.53 | Low | 27.52 | High | 28.50 | Mkt Cap | 1.94B |
| Vol | 152.19K | Avg Vol | 267.64K | EPS | -0.92 | P/E | -30.82 | Forward P/E | -13.26 |
| Beta | 1.28 | Short Ratio | 7.04 | Inst. Own | 70.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 23.93 | 200-d Avg | 17.34 | 1yr Est | 39.50 |
GHRS News
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher
GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea
Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session
Health officials explored restricting specific antidepressants among SSRI drugs-sources
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainer
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, and the headline were update
